$5946 | SAVE $1,049 | Single User
$11892 | SAVE $2,098 | Site License
$17837 | SAVE $3,148 | Enterprise License

Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024

Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024
[Lowest Price Guaranteed: $5,946]

Published by Global Data: 03 Nov 2015 | 27214 | In Stock
Related Topics: Dermatitis , Drug

Introduction

Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024

Summary

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of GlobalData’s 2014 to 2024 forecast, Sanofi/Regeneron’s dupilumab is expected to reshape the adult moderate and severe treatment landscape and to slowly enter the market for younger patients with milder forms of the disease.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US.

Overall, topical moisturizers/emollients will remain the mainstay of therapy across all disease severities in the 5EU and will serve as a key growth driver in the atopic dermatitis market in the 5EU. In terms of systemic therapy, cyclosporine and antihistamines are also important drivers of growth, accounting for the majority of sales in the 5EU, with the former drug being used predominantly in the severe patient group, and the latter across all severities for inducing drowsiness to help patients control night-time itching.

Scope

- Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in 5EU including product Atopic Dermatitiscription, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in 5EU from 2014-2024.

- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Atopic Dermatitis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2014-2024 in 5EU.

Table of Contents
for Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024

  • 1 Table of Contents

    1 Table of Contents 2

    1.1 List of Tables 5

    1.2 List of Figures 7

    2 Introduction 8

    2.1 Catalyst 8

    2.2 Related Reports 8

    2.3 Upcoming Related Reports 9

    3 Disease Overview 10

    3.1 Etiology and Pathophysiology 10

    3.1.1 Etiology 10

    3.1.2 Pathophysiology 11

    3.2 Symptoms 15

    4 Disease Management 17

    4.1 Diagnosis and Treatment Overview 17

    4.1.1 Diagnosis 17

    4.1.2 Treatment Guidelines 19

    4.1.3 Leading Prescribed Drugs for the Treatment of Atopic Dermatitis 21

    4.1.4 Clinical Practice 23

    4.2 5EU 24

    5 Competitive Assessment 32

    5.1 Overview 32

    5.2 Strategic Competitor Assessment 33

    5.3 Product Profiles - Major Brands 34

    5.3.1 Protopic (tacrolimus) 34

    5.3.2 Elidel 42

    5.3.3 Cyclosporine (numerous generic names) 47

    5.3.4 Other Therapeutic Drug Classes Used in Atopic Dermatitis 52

    5.4 Product Profiles - Off-Label Therapies 54

    5.4.1 Xolair (omalizumab) 54

    5.4.2 Actimmune (interferon gamma-1b) 59

    6 Opportunity and Unmet Need 64

    6.1 Overview 64

    6.1.1 A Systemic Drug for Severe Recalcitrant Patients 65

    6.1.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach 68

    6.1.3 A Drug that Effectively Controls Patients’ Pruritus 72

    6.1.4 Further Research into the Pathophysiology of Atopic Dermatitis 74

    6.1.5 A Drug that Induces Disease Remission 77

    6.1.6 Improved Quality of Life for Both Patients and their Carers 78

    7 Pipeline Assessment 81

    7.1 Overview 81

    7.2 Clinical Trial Mapping 82

    7.2.1 Clinical Trials by Therapy Type 82

    7.3 Promising Drugs in Clinical Development 83

    7.3.1 Dupilumab (SAR231893/ REGN668) 86

    7.3.2 AN2728 100

    7.3.3 Other Drugs in Development 112

    8 Market Outlook 114

    8.1 5EU 114

    8.1.1 Forecast 114

    8.1.2 Key Events 119

    8.1.3 Drivers and Barriers 119

    9 Appendix 124

    9.1 Bibliography 124

    9.2 Abbreviations 137

    9.3 Methodology 139

    9.4 Forecasting Methodology 139

    9.4.1 Diagnosed Atopic Dermatitis Patients 139

    9.4.2 Percent Drug-treated Patients 140

    9.4.3 Drugs Included in Each Therapeutic Class 140

    9.4.4 Launch and Patent Expiry Dates 140

    9.4.5 General Pricing Assumptions 141

    9.4.6 Individual Drug Assumptions 142

    9.4.7 Generic Erosion 144

    9.4.8 Pricing of Pipeline Agents 144

    9.5 Physicians and Specialists Included in this Study 145

    9.6 Primary Research - Prescriber Survey 147

    9.7 About the Authors 148

    9.7.1 Author 148

    9.7.2 Reviewer 148

    9.7.3 Epidemiologist 149

    9.7.4 Global Director of Therapy Analysis and Epidemiology 149

    9.7.5 Global Head of Healthcare 150

    9.8 About GlobalData 151

    9.9 Disclaimer 151

List Of Tables
in Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024

1.1 List of Tables

Table 1: Symptoms of Atopic Dermatitis 16

Table 2: Treatment Guidelines for Atopic Dermatitis 21

Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2014 23

Table 4: Country Profile - 5EU 30

Table 5: Leading Treatments for Atopic Dermatitis, 2014 34

Table 6: Product Profile - Protopic 36

Table 7: Clinical Response Data of Protopic (0.03% and 0.1%) versus Vehicle Ointment at Week 12 from One Study in Pediatric Patients and Two Combined Studies in Adult Patients 37

Table 8: Protopic SWOT Analysis, 2015 40

Table 9: Global Sales Forecasts ($m) for Protopic, 2014-2024 42

Table 10: Product Profile - Elidel 43

Table 11: Combined Clinical Efficacy Results of Elidel versus Vehicle Cream at Week 6 from Two Phase III Studies 44

Table 12: Elidel SWOT Analysis, 2015 46

Table 13: Global Sales Forecasts ($m) for Elidel, 2014-2024 47

Table 14: Product Profile - Cyclosporine 49

Table 15: Cyclosporine SWOT Analysis, 2015 51

Table 16: Global Sales Forecasts ($m) for Cyclosporine, 2014-2024 52

Table 17: Summary of Other Therapeutic Classes for Atopic Dermatitis, 2015 53

Table 18: Product Profile - Xolair 55

Table 19: Xolair SWOT Analysis, 2015 57

Table 20: Global Sales Forecasts ($m) Xolair, 2014-2024 58

Table 21: Product Profile - Actimmune 60

Table 22: Actimmune SWOT Analysis, 2015 62

Table 23: Global Sales Forecasts ($m) Actimmune, 2014-2024 63

Table 24: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment 65

Table 25: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2015 68

Table 26: Late-Stage Atopic Dermatitis Pipeline, 2015 85

Table 27: Product Profile - Dupilumab 88

Table 28: Ongoing Clinical Trials of Dupilumab in Atopic Dermatitis Patients, as of December 2014 92

Table 29: Dupilumab SWOT Analysis, 2015 98

Table 30: Global Sales Forecasts ($m) for Dupilumab, 2014-2024 99

Table 31: Product Profile - AN2728 102

Table 32: Efficacy Results for AN2728 in Mild to Moderate Adolescent Atopic Dermatitis Patients (Day 29) 103

Table 33: AN2728 SWOT Analysis, 2015 109

Table 34: Global Sales Forecasts ($m) for AN2728, 2014-2024 111

Table 35: Drugs in Early-stage Clinical Development for Atopic Dermatitis, 2015 112

Table 36: Sales Forecasts ($m) for Atopic Dermatitis in the 5EU, 2014-2024 117

Table 37: Key Event Impacting Sales for Atopic Dermatitis in 5EU, 2014-2024 119

Table 38: Atopic Dermatitis Market in 5EU - Drivers and Barriers, 2014-2024 119

Table 39: Key Launch Dates 140

Table 40: Key Patent Expiries 140

Table 41: Physicians Surveyed, By Country 147

List Of Figures, Charts and Diagrams
in Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024

1.2 List of Figures

Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin 13

Figure 2: Flow Chart of the Diagnosis and Management of Atopic Dermatitis 20

Figure 3: Atopic Dermatitis Therapeutics - Clinical Trials by Therapy Type and Development Stage, October 2015 83

Figure 4: Atopic Dermatitis - Phase III Pipeline, December 2014 84

Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Atopic Dermatitis, 2014-2024 85

Figure 6: Sales for Atopic Dermatitis in 5EU by Drug Class, 2014-2024 118

Additional Details

Publisher

Global Data

Publisher Information

Reference

27214 | GDHC303CFR

Number of Pages

152

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel Therapies
Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness...
15 Nov 2018 by GBI Research USD $4,246 (normally
USD $4,995)
More Info
SAVE 15% today! Atopic Dermatitis - Pipeline Review, H1 2017
Atopic Dermatitis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and...
15 Mar 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024SummaryAlthough the...
03 Nov 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024
Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024SummaryAlthough the past decade has ...
03 Nov 2015 by Global Data USD $4,246 (normally
USD $4,995)
More Info
SAVE 15% today! Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024
Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024SummaryAlthough the past decade h...
03 Nov 2015 by Global Data USD $4,246 (normally
USD $4,995)
More Info
SAVE 15% today! Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024
Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024SummaryAlthough the past decade has...
03 Nov 2015 by Global Data USD $5,946 (normally
USD $6,995)
More Info
SAVE 15% today! Atopic Dermatitis - Current and Future Players
Atopic Dermatitis - Current and Future PlayersSummaryGlobalData has released its pharma report, “Ato...
03 Nov 2015 by Global Data USD $2,546 (normally
USD $2,995)
More Info
SAVE 15% today! Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024
Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024SummaryAlthough the past decade has ...
03 Nov 2015 by Global Data USD $4,246 (normally
USD $4,995)
More Info
SAVE 15% today! Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024
Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024SummaryAlthough the past decade h...
03 Nov 2015 by Global Data USD $4,246 (normally
USD $4,995)
More Info
SAVE 15% today! Atopic Dermatitis - Current and Future Players
Atopic Dermatitis - Current and Future PlayersSummaryGlobalData has released its pharma report, “Ato...
03 Nov 2015 by Global Data USD $2,546 (normally
USD $2,995)
More Info

This report is published by Global Data

Download Free Report Summary PDF

Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...